Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a recent report, Stifel analysts gave their bullish analysis of several stocks. Here’s a breakdown of what the analysts had to say about three of their Buy-rated names.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analysts see “blockbuster potential” for Jazz’s defibrotide drug that Jazz acquired full rights to in 2014. The drug, used to treat hepatic veno-occlusive disease, has already launched in Europe and is working its way down the U.S. regulatory pathway.
Analysts believe that that defibrotide will see expanded uses in the future and that the drug could eventually surpass the value of Jazz’s flagship drug, Xyrem.
Analysts feel that the market is not fully appreciating the potential of defibrotide, and they name Jazz as a top pick and place a $225.00 target on the stock.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH)
The major case analysts make for Norwegian Cruise Line is a valuation case. Analysts note that the stock currently trades at just about 12x their 2016 earnings per share estimates for the company. Stifel is predicting 20 percent earnings growth for the company in each of the next three years.
Norwegian Cruise's stock jumped by more than 7 percent on Wednesday after Tuesday’s earnings beat, and Stifel sees more even more upside to come.
The firm has a Buy rating on the stock and a $49.00 price target.
WellCare Health Plans, Inc. (NYSE: WCG)
After a shaky past that includes wild swings in share price, an FBI raid and other drama, Stifel analysts are convinced that WellCare finally has a management team that understands the importance of both executing the company’s business plan and communicating clearly with shareholders.
Analysts predict that WellCare’s revenue and earnings will double in the next few years.
Stifel currently has a Buy rating on WellCare and a $100.00 price target on the stock.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.